The dysregulation of TLR-4 signaling may change the ligand binding and balance between pro- and anti-inflammatory cytokines, creating a pro-inflammatory environment that favors tumor growth, thereby modulating the risk of CRC [10]. The gene discussed is TLR4; the disease is colorectal carcinoma.